Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTXNASDAQ:INDPNASDAQ:NHNASDAQ:ONTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$1.30-0.4%$1.28$0.85▼$4.40$41.67M0.2931,834 shs6,576 shsINDPIndaptus Therapeutics$0.40+25.0%$0.47$0.31▼$2.89$6.41M1.49195,274 shs11.80 million shsNHNantHealth$0.00$0.01$1.24▼$9.75$24K1.8238,073 shs75 shsONTXOnconova Therapeutics$0.85$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics-0.38%+1.57%-5.47%+48.85%-27.65%INDPIndaptus Therapeutics+25.71%+5.43%-16.14%-52.32%-85.51%NHNantHealth0.00%0.00%-93.80%+210.00%-99.72%ONTXOnconova Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKTXAkari TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AINDPIndaptus Therapeutics3.5988 of 5 stars3.55.00.00.03.31.71.3NHNantHealthN/AN/AN/AN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 0.00N/AN/AN/AINDPIndaptus Therapeutics 3.00Buy$8.502,025.00% UpsideNHNantHealth 0.00N/AN/AN/AONTXOnconova Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A($0.03) per shareN/AINDPIndaptus TherapeuticsN/AN/AN/AN/A$1.44 per shareN/ANHNantHealth$67.68M0.00N/AN/A($30.72) per share0.00ONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$10.01MN/A0.00∞N/AN/AN/AN/A8/18/2025 (Estimated)INDPIndaptus Therapeutics-$15.42M-$1.49N/AN/AN/AN/A-177.27%-141.06%8/11/2025 (Estimated)NHNantHealth-$67.78M-$7.65N/A∞N/A-94.67%N/A-39.82%N/AONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%N/ALatest NH, ONTX, AKTX, and INDP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025INDPIndaptus Therapeutics-$0.41-$0.32+$0.09-$0.32N/AN/A3/13/2025Q4 2024INDPIndaptus Therapeutics-$0.41-$0.38+$0.03-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ANHNantHealthN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.290.29INDPIndaptus TherapeuticsN/A3.423.42NHNantHealthN/A0.640.64ONTXOnconova TherapeuticsN/A2.792.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%INDPIndaptus Therapeutics7.06%NHNantHealth4.50%ONTXOnconova Therapeutics7.95%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.90%INDPIndaptus Therapeutics29.50%NHNantHealth61.30%ONTXOnconova Therapeutics3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.18 million16.25 millionNot OptionableINDPIndaptus Therapeutics616.03 million9.96 millionNot OptionableNHNantHealth3407.70 million2.98 millionNot OptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableNH, ONTX, AKTX, and INDP HeadlinesRecent News About These CompaniesOnconova Therapeutics Regains Compliance with Nasdaq Continued Listing RequirementAugust 9, 2024 | br.advfn.comTRAW Traws Pharma, Inc.July 20, 2024 | seekingalpha.comOnconova and Trawsfynydd merge to form Traws PharmaApril 4, 2024 | uk.investing.comTraws Pharma Full Year 2023 Earnings: Beats ExpectationsApril 4, 2024 | finance.yahoo.comNewtown’s Onconova Therapeutics Secures $14 Million and New CEO in Merger with TrawsfynyddApril 3, 2024 | msn.comOnconova Acquires Trawsfynydd To Form Traws PharmaApril 2, 2024 | markets.businessinsider.comTraws Pharma Announces New Employee Inducement GrantsApril 2, 2024 | globenewswire.comOnconova to Unveil New Rigosertib Study Results at Cancer Research MeetingMarch 12, 2024 | msn.comAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)March 11, 2024 | markets.businessinsider.comOnconova Therapeutics’ Rigosertib Poster Selected for AACR 2024March 8, 2024 | finance.yahoo.comOnconova Therapeutics' Rigosertib Poster Selected for AACR 2024March 8, 2024 | globenewswire.comOnconova Therapeutics Inc (ONTX)February 13, 2024 | investing.comOnconova Therapeutics, Inc. (ONTX)January 23, 2024 | finance.yahoo.comOnconova Therapeutics Stock (NASDAQ:ONTX) Dividends: History, Yield and DatesDecember 21, 2023 | benzinga.comOnconova stock falls 10% on preclinical data for lymphoma drugDecember 12, 2023 | msn.comOnconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell LymphomaDecember 12, 2023 | finance.yahoo.comOnconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’sDecember 8, 2023 | finance.yahoo.comOnconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity ConferenceNovember 28, 2023 | finance.yahoo.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call TranscriptNovember 16, 2023 | finance.yahoo.comOnconova Therapeutics, Inc.: Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial ResultsNovember 16, 2023 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookUnitedHealth Insiders Double Down: Is UNH Stock a Value Play?By Jeffrey Neal Johnson | May 19, 2025View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?3 Trades Members of Congress Are Making Right NowBy Chris Markoch | May 23, 2025View 3 Trades Members of Congress Are Making Right NowTarget's Big Bet: Is It a Cheap Stock or a Value Trap? By Jeffrey Neal Johnson | May 29, 2025View Target's Big Bet: Is It a Cheap Stock or a Value Trap? NH, ONTX, AKTX, and INDP Company DescriptionsAkari Therapeutics NASDAQ:AKTX$1.30 -0.01 (-0.38%) Closing price 05/29/2025 03:56 PM EasternExtended Trading$1.32 +0.02 (+1.85%) As of 05/29/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Indaptus Therapeutics NASDAQ:INDP$0.40 +0.08 (+25.00%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.37 -0.03 (-7.25%) As of 05/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.NantHealth NASDAQ:NH$0.0031 0.00 (0.00%) As of 05/28/2025NantHealth, Inc. engages in the provision of enterprise solutions that help businesses transform complex data into actionable insights. It is also involved in marketing solutions as a comprehensive integrated solution that includes clinical decision support, payer engagement solutions, data analysis, and network monitoring and management. The company was founded by Patrick Soon-Shiong on July 7, 2010 and is headquartered in Morrisville, NC.Onconova Therapeutics NASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
